Efficacy News and Research

RSS

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Women vaccinated with one dose of a human papillomavirus (HPV) vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

4 Nov 2013

Current percutaneous techniques shed light on treatment of heart valve leakage

A Paravalvular regurgitation, or leakage, commonly affects valvular prostheses, particularly artificial valves placed percutaneously according to data presented at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) conference.

4 Nov 2013

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.

1 Nov 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today reported preliminary data from the Company's ongoing extension study of a Phase I/II clinical trial with its lead product Glassia® to treat pediatric patients with a recently diagnosed type 1 diabetes (T1D).

31 Oct 2013

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.

31 Oct 2013

Researcher receives prestigious NCI grant to investigate unexplored area of cancer research

The National Cancer Institute's (NCI) new Provocative Questions research funding program has awarded a prestigious grant to a researcher at Roswell Park Cancer Institute (RPCI) to investigate a promising but neglected or unexplored area of cancer research.

31 Oct 2013

UofL researcher enters into license and research collaboration agreement with Novartis

The University of Louisville today announced that researcher Dr. Suzanne Ildstad, representing Regenerex LLC, has entered into a license and research collaboration agreement with Novartis to provide access to stem cell technology that has the potential to help transplant patients avoid taking anti-rejection medicine for life and could serve as a platform for treatment of other diseases.

31 Oct 2013

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.

30 Oct 2013

Some safety questions remain unanswered in expedited FDA drug approvals

Fewer patients were studied as part of expedited reviews of new drugs approved by the U.S. Food and Drug Administration (FDA) in 2008 and some safety questions remain unanswered, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

30 Oct 2013

Researchers develop new substance that quickly and effectively kills multi-resistant bacteria

In Europe alone, more than 25,000 people die each year from infections caused by multi-resistant bacteria. Researchers from University of Copenhagen have now developed and characterized a substance that quickly and effectively kills the virulent bacteria. The substance employs a multifunctional mechanism that reduces the risk of antibiotic resistance. The findings have recently been published in the scientific journal Chemistry & Biology.

30 Oct 2013

Clinical trial finds COREVALVE reduces rate of death, stroke in patients with aortic stenosis

In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery.Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

30 Oct 2013

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Firstly, actinic keratosis (AK) is a common dermatological condition caused by cumulative exposure to the sun. Providing patients with effective treatment is very important, as AK can lead to forms of non-melanoma skin cancer (NMSC) if not diagnosed and treated early. In fact, two in three cases of squamous cell carcinoma (a common form of skin cancer), begin as AK.

29 Oct 2013

Researchers identify possible causes of colorectal cancer resistance to bevacizumab drug

A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor.

29 Oct 2013

Cytrx announces Q3 2013 financial results, provides clinical update

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

29 Oct 2013

Loyola researchers publish first ever study of moral distress experienced by nurses in burn ICU

Loyola University Medical Center researchers have published the first ever study of emotional and psychological anguish, known as "moral distress," experienced by nurses in an intensive care unit for burn patients.

29 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

VisionGate's Cell-CT platform can detect lung cancer in sputum samples with high specificity

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT-, can detect lung cancer in sputum samples with high sensitivity and specificity. The data was presented at the International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer.

29 Oct 2013

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

28 Oct 2013

Efficacy News and Research

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Current percutaneous techniques shed light on treatment of heart valve leakage

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

Researcher receives prestigious NCI grant to investigate unexplored area of cancer research

UofL researcher enters into license and research collaboration agreement with Novartis

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

Some safety questions remain unanswered in expedited FDA drug approvals

Researchers develop new substance that quickly and effectively kills multi-resistant bacteria

Clinical trial finds COREVALVE reduces rate of death, stroke in patients with aortic stenosis

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Researchers identify possible causes of colorectal cancer resistance to bevacizumab drug

Cytrx announces Q3 2013 financial results, provides clinical update

Loyola researchers publish first ever study of moral distress experienced by nurses in burn ICU

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

VisionGate's Cell-CT platform can detect lung cancer in sputum samples with high specificity

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News